INC Research has launched the Psychiatry Catalyst Site Network as part of its Catalyst program introduced in 2016 to support collaborations with global clinical research sites. The program aims to enhance patient focus and optimize study delivery to improve predictability and increased efficiency for customers. INC selected 32 high-performing clinical research sites to participate in the initial launch of the new network, which was formed to respond growth and strong pipeline of psychiatric studies.

“Many of the newer schizophrenia and depression studies require a greater commitment from investigators than in previous years, and INC’s Catalyst program provides a strong foundation by establishing clear and mutually agreeable expectations regarding the administrative aspects of running a clinical trial from the onset,” said Tom Zoda, Ph.D., executive vice president and general manager, CNS Clinical Development, INC Research. “By easing the administrative burden for sites, we are better positioning them to spend more time focusing on enrollment of suitable patients and engagement of their caregivers. Our goal through the Psychiatry Catalyst Site Network is to raise the caliber and quality of work in psychiatry clinical trials for the ultimate benefit of patients in need of these medications.”

Sites selected for the Psychiatric Catalyst Site network will work with each other and with INC Research in an effort to deliver studies more quickly and more predictably. “I am excited to be part of INC’s Psychiatry Catalyst Site Network, which builds on its Protocol Review Site Advocacy Group (SAG) implemented in 2015 to engage sites earlier on in the scientific and operational aspects of CNS clinical trials to improve patient engagement and ultimately study delivery,” said David Walling, Ph.D., a principal investigator with Collaborative Neuroscience Network, LLC.  

Through the Protocol Review SAG and the Psychiatry Catalyst Site Network, INC aims to streamline processes to improve the patient experience and accelerate drug development.